Clinical trial
Capecitabine and Irinotecan in Treating Patients With Locally Advanced…
NCT00022698 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00022698 |
|---|---|
| Title | Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer |
| Official title | A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Irinotecan |
| Enrollment | 67 |
| Start date | May 1, 2001 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 15, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: